Meeting
2022 ASCO Annual Meeting
Optimal timing and interval of imaging for metastatic breast cancer.
Authors
Shruti Rajesh Patel
Stanford University, Stanford, CA
Shruti Rajesh Patel , Haruka Itakura , George W. Sledge Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 1106)
DOI
10.1200/JCO.2022.40.16_suppl.1106
Abstract #
1106
Poster Bd #
483
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).
First Author: Erica Michelle Stringer-Reasor
Poster
2020 ASCO Virtual Scientific Program
SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).
First Author: Santiago Escrivá
Poster
2018 ASCO Annual Meeting
Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR+) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).
First Author: Wolfgang Eiermann
Poster
2017 ASCO Annual Meeting
Assessment of ESR1 and ERBB2 mutations in estrogen receptor positive (ER+) metastatic breast cancers (MBC).
First Author: Gargi D. Basu